Loading news...
Regatta Capital Group LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,062 shares of the biopharmaceutical company's stock, valued at approximately $451,000. Several other hedge funds also recently made
E. Ohman J or Asset Management AB grew its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 516.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 324,647 shares of the biopharmaceutical company's stock after acquiring an additional 271,973 shares
Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
Confluence Investment Management LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 1.7% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 952,946 shares of the biopharmaceutical company's stock after selling 16,861 shares during the
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 12, 2026 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and.
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio R.
Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing.
Guru Stock PicksVanguard Health Care Fund has made the following transactions:Reduce in ARGX by 14.38%Sold out in PACSAdd in CLDX by 3.64%New position in PTGXCI
Officials pledge ‘massive savings' as companies agree to offer drugs at prices paid in other wealthy countries
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug prices to cheaper ones abroad. Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk have already struck deals with the Trump administration to cut prices.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company's long-standing commitment to U.S.-based innovation, affordability, and global health leadership. “This agreement reflects a foundational commitment to both affordability and future innovation, a commitment that we have long seen as essential to shaping the future of healthcare,” said Daniel O'Day, C.
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
GILD???s HIV franchise gains momentum as twice-yearly PrEP Yeztugo wins FDA approval and late-stage data back a new single-tablet regimen.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Lega.
Gilead Sciences (GILD) closed the most recent trading day at $121.36, moving +2.17% from the previous trading session.
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
Inflation, interest rates, and broader economic uncertainty have forced companies across many sectors to prioritize efficiency. In this environment, it can be particularly challenging for firms to maintain cash flow, which is vital to their continued healthy operations and growth.
Gilead Sciences said on Monday its experimental HIV treatment met the main goal in a late-stage trial.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to a fixed-dose combination of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non.